Array gets national recommendation for use of its drug combination

BOULDER — The National Comprehensive Cancer Network has updated its clinical practice guidelines for colon and rectal cancer that includes a drug combination from Array BioPharma Inc. (Nasdaq: ARRY).

The update includes Braftovi in combination with Mektovi and an anti-EGFR antibody as a treatment for patients with BRAF-mutant metastatic colorectal cancer, after the failure of one or two prior lines of therapy for metastatic disease, Array said in a news release. The BRAF mutation usually has a poor prognosis compared to patients with colorectal cancer who do not have the mutation. There are currently no FDA therapies…